• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by BillionToOne Inc.

    1/20/26 7:46:53 PM ET
    $BLLN
    Medical Specialities
    Health Care
    Get the next $BLLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    BillionToOne

    (Name of Issuer)


    Class A common stock

    (Title of Class of Securities)


    090168105

    (CUSIP Number)


    Lucas De Four
    Square Victoria Regina 1,
    Sint-Joost-ten-Node, C9, 1210
    0032477 58 95 42


    Folake Ayoola, Esq.
    1900 N Street, NW,
    Washington, DC, 20036
    (202) 346-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/06/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Hummingbird Ventures Management NV
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    7,887,237.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    7,887,237.00
    11Aggregate amount beneficially owned by each reporting person

    7,887,237.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    19.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's initial public offering (the "IPO") prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Hummingbird Opportunity Fund II CommV
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,631,664.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,631,664.00
    11Aggregate amount beneficially owned by each reporting person

    2,631,664.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.55 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Hummingbird Ventures III CommV
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,580,833.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,580,833.00
    11Aggregate amount beneficially owned by each reporting person

    2,580,833.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.43 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Hummingbird Dragons CommV
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,015,118.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,015,118.00
    11Aggregate amount beneficially owned by each reporting person

    2,015,118.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.02 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Hummingbird Collective CommV
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    18,845.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    18,845.00
    11Aggregate amount beneficially owned by each reporting person

    18,845.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.05 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    HB&Q NV
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    640,727.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    640,727.00
    11Aggregate amount beneficially owned by each reporting person

    640,727.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.60 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Firat Ileri
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CYPRUS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    7,887,237.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    7,887,237.00
    11Aggregate amount beneficially owned by each reporting person

    7,887,237.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    19.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Barend Van den Brande
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    7,887,237.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    7,887,237.00
    11Aggregate amount beneficially owned by each reporting person

    7,887,237.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    19.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    090168105


    1 Name of reporting person

    Lukas Decoster
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    BELGIUM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    7,887,237.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    7,887,237.00
    11Aggregate amount beneficially owned by each reporting person

    7,887,237.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    19.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    For item 13: This calculation is based upon 40,167,729 Class A common stock shares outstanding as of November 6, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class A common stock
    (b)Name of Issuer:

    BillionToOne
    (c)Address of Issuer's Principal Executive Offices:

    1035 O'Brien Drive, Menlo Park, CALIFORNIA , 94025.
    Item 1 Comment:
    This Schedule 13D relates to the Class A common stock of BilliontoOne, Inc., a Delaware corporation (the "Issuer"). The principal executive offices of the Issuer are located at 1035 O'Brien Drive, Menlo Park, CA 94025.
    Item 2.Identity and Background
    (a)
    Hummingbird Ventures Management NV, a limited liability company (naamloze vennootschap) that was organized under the laws of Belgium; Hummingbird Opportunity Fund II CommV, a limited partnership (commanditaire vennootschap) that was organized under the laws of Belgium; Hummingbird Ventures III CommV, a limited partnership (commanditaire vennootschap) that was organized under the laws of Belgium; Hummingbird Dragons CommV, a limited partnership (commanditaire vennootschap) that was organized under the laws of Belgium; Hummingbird Collective CommV, a limited partnership (commanditaire vennootschap) that was organized under the laws of Belgium; HB&Q NV, a limited liability company (naamloze vennootschap) that was organized under the laws of Belgium; Firat Ileri, an individual citizen of Cypress; Barend Van den Brande, an individual citizen of Belgium; and Lukas Decoster, an individual citizen of Belgium (collectively, the "Reporting Persons").
    (b)
    The address for the Reporting Persons is Square Victoria Regain 1, 1210 Sint-Joost-ten-Node, Belgium.
    (c)
    Each of Hummingbird Opportunity Fund II CommV, Hummingbird Ventures III CommV, Hummingbird Dragons CommV, Hummingbird Collective CommV, and HB&Q NV (the "Hummingbird Funds"), with a principle address of Square Victoria Regain 1, 1210 Sint-Joost-ten-Node, Belgium are alternative investment funds under Belgian law. Hummingbird Ventures Management NV is the managing member of Hummingbird Opportunity Fund II CommV, Hummingbird Ventures III CommV, Hummingbird Dragons CommV, Hummingbird Collective CommV, and HB&Q NV. Fiat Ileri, Barend Van den Brande, and Lukas Decoster are partners of Hummingbird Ventures Management NV with a principle address of Square Victoria Regain 1, 1210 Sint-Joost-ten-Node, Belgium and may be deemed to have shared voting and investment power over the shares held by the Hummingbird Funds. Fiat Ileri serves as a director of the Issuer.
    (d)
    No
    (e)
    No
    (f)
    C9
    Item 3.Source and Amount of Funds or Other Consideration
     
    Prior to the Issuer's IPO, in March 2019, Hummingbird Ventures III CommV purchased an aggregate of 2,260,520 shares of Series A-6 redeemable convertible preferred stock (the "Series A-6 Preferred"), in February 2020, HB&Q NV and Hummingbird Ventures III CommV purchased an aggregate of 961,090 shares of Series B-2 redeemable convertible preferred stock (the "Series B-2 Preferred"), in November 2020, Hummingbird Opportunity Fund II CommV purchased an aggregate of 20,000 shares of Series A-1 redeemable convertible preferred stock (the "Series A-1 Preferred"), in November 2020, Hummingbird Opportunity Fund II CommV purchased an aggregate of 33,000 shares of Series A-2 redeemable convertible preferred stock (the "Series A-2 Preferred"), in February 2021, Hummingbird Opportunity Fund II CommV and Hummingbird Collective CommV purchased an aggregate of 2,280,222 shares of Series B-1 redeemable convertible preferred stock (the "Series B-1 Preferred"), in April 2021, Hummingbird Opportunity Fund II CommV purchased an aggregate of 179,999 shares of Class A common stock of the Issuer (the "Common Stock"), in September 2022, Hummingbird Dragons CommV, and Hummingbird Opportunity Fund II CommV purchased an aggregate of 1,706,303 shares of Series C redeemable convertible preferred stock (the "Series C Preferred") and in May 2024, Hummingbird Dragons CommV purchased an aggregate of 446,103 shares of Series D redeemable convertible preferred stock (the "Series D Preferred" and, together with the Series A-1 Preferred, the Series A-2 Preferred, the Series A-6 Preferred, the Series B-1 Preferred, the Series B-2 Preferred and the Series C Preferred, the "Preferred Stock"). The aggregate purchase price of the foregoing securities was $93,673,956.50. Each share of Preferred Stock converted automatically into a share of the Issuer's Class A common stock, on a one-for-one basis, immediately prior to the completion of the IPO. The response to Item 6 below is incorporated herein by reference.
    Item 4.Purpose of Transaction
     
    The Shares reported herein as being beneficially owned by the Reporting Persons were acquired for investment purposes. The Reporting Persons acquired beneficial ownership of the shares as described in this Schedule 13D for investment purposes and intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including but not limited to the Issuer's business, prospects, financial position and strategic direction, price levels of the shares, conditions in the securities markets, and general economic and industry conditions, each Reporting Person may in the future take such actions with respect to its investment in the Issuer as it deems appropriate, including changing its current intentions, with respect to any or all matters required to be disclosed in this Schedule 13D. Fiat Ileri is a director of the Issuer. Consistent with the Reporting Persons' investment purposes, the Reporting Persons may engage in communications with, without limitation, one or more shareholders of the Issuer, management of the Issuer or one or more members of the board of directors of the Issuer, and may make suggestions concerning the Issuer's operations, prospects, business and financial strategies, strategic direction and transactions, assets and liabilities, business and financing alternatives and such other matters as the Reporting Persons may deem relevant to their investment in the Issuer. The Reporting Persons expect that they will, from time to time, review their investment position in the Issuer and may make additional purchases of Class A common stock of the Issuer (or other securities convertible or exercisable into Class A common stock) in the open market or in privately negotiated transactions, or hold or dispose of all or part of their investments in the shares, depending upon the Reporting Persons' evaluation of the Issuer's business, prospects, financial condition and strategic direction, the market for the shares, other opportunities available to the Reporting Persons, general economic conditions, stock market conditions and other factors. Except as set forth in this Item 4 or Item 6 below, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act.
    Item 5.Interest in Securities of the Issuer
    (a)
    The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5. Pursuant to Rule 13d-3 under the Act, each of the Reporting Persons may be deemed to beneficially own and share voting and dispositive power in respect of 40,167,729 Shares. This calculation is based upon 40,167,729 Class A common stock shares outstanding as of September 30, 2025, as disclosed on the Issuer's IPO prospectus filed with the Securities and Exchange Commission on November 6, 2025.
    (b)
    N/A
    (c)
    To the knowledge of the Reporting Persons, no person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Shares beneficially owned by the Reporting Persons identified in this Item 5.
    (d)
    None
    (e)
    N/A
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    None
    Item 7.Material to be Filed as Exhibits.
     
    N/A

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Hummingbird Ventures Management NV
     
    Signature:/s/ Lukas Decoster
    Name/Title:49/9 CommV, represented by its permanent representative Lukas Decoster, Director
    Date:01/20/2026
     
    Hummingbird Opportunity Fund II CommV
     
    Signature:/s/ Firat Ileri
    Name/Title:Hummingbird Ventures Management NV, its Manager; Firat Ileri, Permanent Representative
    Date:01/20/2026
     
    Hummingbird Ventures III CommV
     
    Signature:/s/ Firat Ileri
    Name/Title:Hummingbird Ventures Management NV, its Manager; Firat Ileri, Permanent Representative
    Date:01/20/2026
     
    Hummingbird Dragons CommV
     
    Signature:/s/ Firat Ileri
    Name/Title:Hummingbird Ventures Management NV, its Manager; Firat Ileri, Permanent Representative
    Date:01/20/2026
     
    Hummingbird Collective CommV
     
    Signature:/s/ Firat Ileri
    Name/Title:Hummingbird Ventures Management NV, its Manager; Firat Ileri, Permanent Representative
    Date:01/20/2026
     
    HB&Q NV
     
    Signature:/s/ Firat Ileri
    Name/Title:Hummingbird Ventures Management NV, its Manager; Firat Ileri, Permanent Representative
    Date:01/20/2026
     
    Firat Ileri
     
    Signature:/s/ Firat Ileri
    Name/Title:Firat Ileri
    Date:01/20/2026
     
    Barend Van den Brande
     
    Signature:/s/ Barend Van den Brande
    Name/Title:Barend Van den Brande
    Date:01/20/2026
     
    Lukas Decoster
     
    Signature:/s/ Lukas Decoster
    Name/Title:Lukas Decoster
    Date:01/20/2026
    Get the next $BLLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLLN

    DatePrice TargetRatingAnalyst
    1/6/2026$120.00Buy
    Guggenheim
    12/1/2025Outperform
    William Blair
    12/1/2025$117.00Hold
    Jefferies
    12/1/2025$150.00Overweight
    Analyst
    12/1/2025$150.00Overweight
    Piper Sandler
    12/1/2025$145.00Buy
    Stifel
    12/1/2025$110.00Equal Weight
    Wells Fargo
    12/1/2025$160.00Buy
    BTIG Research
    More analyst ratings

    $BLLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on BillionToOne with a new price target

    Guggenheim initiated coverage of BillionToOne with a rating of Buy and set a new price target of $120.00

    1/6/26 8:54:21 AM ET
    $BLLN
    Medical Specialities
    Health Care

    William Blair initiated coverage on BillionToOne

    William Blair initiated coverage of BillionToOne with a rating of Outperform

    12/1/25 8:36:56 AM ET
    $BLLN
    Medical Specialities
    Health Care

    Jefferies initiated coverage on BillionToOne with a new price target

    Jefferies initiated coverage of BillionToOne with a rating of Hold and set a new price target of $117.00

    12/1/25 8:27:06 AM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Humming Bird Ventures Management Nv disposed of 7,887,187 shares, acquired 7,887,187 shares and converted options into 7,707,188 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:27:56 PM ET
    $BLLN
    Medical Specialities
    Health Care

    New insider Humming Bird Ventures Management Nv claimed ownership of 179,999 shares (SEC Form 3)

    3 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:25:53 PM ET
    $BLLN
    Medical Specialities
    Health Care

    Director Pagano Anthony was granted 4,896 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/5/26 8:52:49 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    SEC Filings

    View All

    SEC Form DEFA14A filed by BillionToOne Inc.

    DEFA14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:26:02 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by BillionToOne Inc.

    DEF 14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:25:37 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form 10-K filed by BillionToOne Inc.

    10-K - BillionToOne, Inc. (0002070849) (Filer)

    3/11/26 4:55:45 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Leadership Updates

    Live Leadership Updates

    View All

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

    MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee. Mr. Pagano is currently Chief Financial Officer and Executive Vice President of Genmab, a leading international biotechnology company, a position he has held since March 2020. He joined Genmab in December 200

    12/9/25 4:07:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Financials

    Live finance-specific insights

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. To participate in the conference call, please register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast will be available

    2/17/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care